In the past decade, two new classes of antihyperglycemics drugs have been introduced in the clinical practice (sodium-glucose cotransporter-2 inhibitors-SGLT2 and GLP1-receptor agonists-GLP-1RAs) that showed a significant decrease in cardiovascular risk and the progression of DKD [9]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.